Melanoma Clinical Trial

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma

Summary

This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with CMP-001 may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. The addition of CMP-001 to pembrolizumab could improve the ability of the immune system to shrink tumors and to prevent them from returning.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To evaluate the rate of pathologic complete response (pCR) rate in patients in each arm of the trial.

SECONDARY OBJECTIVES:

I. To evaluate the rate of pathologic near-complete/major response (pMR) of the neoadjuvant therapy in each arm.

II. To evaluate the pathologic response rate of un-injected lesions on the combination arm.

III. To evaluate relapse-free survival (RFS) in each arm. IV. To evaluate overall survival (OS) in each arm. V. To evaluate the preoperative radiographic response rate in each arm. VI. To evaluate safety and toxicity of neoadjuvant therapy in each arm.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A:

NEOADJUVANT PHASE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT)/positron emission tomography (PET) at baseline, day 15 of cycle 3, day 1 of every other cycle, and during follow-up.

SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.

ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/PET at baseline, day 15 of cycle 3, day 1 of every other cycle, and during follow-up.

ARM B:

NEOADJUVANT PHASE: Patients receive VLP-encapsulated TLR9 agonist CMP-001 (CMP-001) subcutaneously (SC) on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/PET at baseline, day 15 of cycle 3, day 1 of every other cycle, and during follow-up.

SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.

ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/PET at baseline, day 15 of cycle 3, day 1 of every other cycle, and during follow-up.

After completion of study treatment, patients are followed up at 30 days and then every 3 months if < 2 years from study entry, every 6 months if 2-5 years from study entry, and every 12 months if > 5 years from study entry for up to 10 years (15 years total follow up).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must be >= 18 years of age
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Patient must have a histologic diagnosis of melanoma belonging to the following American Joint Committee on Cancer (AJCC) 8th edition TNM stages:

T0, Tx or T1-4; and
N1b, N2b, N2c, N3b or N3c

Patients may have a presentation with primary melanoma with concurrent regional nodal and/or in-transit metastasis; or patients may have a history of primary melanoma or unknown primary melanoma presenting with clinically detected regional nodal and/or in-transit recurrence; and may belong to any of the following groups:

Primary cutaneous melanoma with clinically apparent regional lymph node metastases and/or in-transit metastases
Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin
Primary cutaneous melanoma with concurrent nodal disease involving a single (or multiple) regional nodal group(s) if considered potentially surgically resectable at baseline
Clinically detected nodal melanoma (if single site) arising from an unknown primary

In-transit cutaneous metastases with or without regional lymph node involvement permitted if considered potentially surgically resectable at baseline

NOTE: Patients with mucosal and/or uveal melanoma are not eligible for the study
Patient must be a candidate for definitive surgery and have met with the treating surgical oncologist prior to randomization

Patient must have the presence of injectable and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, documented by scans obtained within 4 weeks prior to randomization

NOTE: Injectable disease is defined as an accessible lesion in the skin, subcutaneous tissue or lymph nodes (LN) close to the skin and palpable by physical examination or approachable with ultrasound guidance
Absolute neutrophil count (ANC) >= 1,500 /mcL (obtained within 4 weeks prior to randomization)
Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L (obtained within 4 weeks prior to randomization)
Platelets >= 100,000 / mcL (obtained within 4 weeks prior to randomization)
Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) or measured or calculated creatinine clearance > 60 mL/min (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl] for patients with creatinine levels > 1.5 x institutional ULN) (obtained within 4 weeks prior to randomization)
Serum total bilirubin =< 1.5 x institutional ULN; for total bilirubin levels > 1.5 x ULN, but =< 3 x ULN, the direct bilirubin must be =< the institutional ULN (obtained within 4 weeks prior to randomization)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained within 4 weeks prior to randomization)
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization)
Activated partial thromboplastin time (aPTT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization)
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to randomization are eligible for this trial.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

Exclusion Criteria:

Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study. Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and COVID-19 (Note: intranasal influenza vaccines, such as Flu-Mist are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events)
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A urine or serum pregnancy test must be repeated within 72 hours prior to receiving the first dose of pembrolizumab if the test done for eligibility/randomization is done outside of this 72 hour window. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or abstaining from sexual intercourse from time of randomization, while on study treatment, and continue for 26 weeks after the last dose of protocol treatment
Patient must not have received prior systemic therapy for melanoma including systemic therapy with an anti-PD-1, anti-PD-L1, anti-CTLA-4, BRAF/MEK inhibitor combination and/or TLR-9 agonist

Patient must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization, except as noted here

Patients who are currently receiving steroids at a dose of prednisone =< 5 mg daily (or equivalent) are permitted to enroll
Patients who require topical, ophthalmologic and inhalational steroids are permitted to enroll
Patients with hypothyroidism who are stable on hormone replacement are permitted to enroll
Patients who require active immunosuppression with corticosteroids at a dose of prednisone > 5 mg daily (or equivalent) for any reason are ineligible
Patients with adrenal insufficiency are ineligible
Patients who have developed autoimmune disorders of grade 4 while on prior immunotherapy are not permitted to enroll on this study. Patients who developed autoimmune disorders of grade =< 3 may enroll if the disorder has resolved to grade =< 1 and the patient has been off systemic corticosteroids at doses > 5 mg for at least 2 weeks prior to randomization
Patients with a history of brain metastases are not eligible for this study as they do not meet the eligibility staging criteria
Patient must not have had an allogeneic tissue/solid organ transplant
Patient must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
Patient must not have an active infection requiring systemic therapy
Patient must not have a known psychiatric or substance abuse disorder that would interfere with the patient's ability to cooperate with the requirements of the study

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

54

Study ID:

NCT04708418

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 137 Locations for this study

See Locations Near You

Anchorage Associates in Radiation Medicine
Anchorage Alaska, 98508, United States
Alaska Breast Care and Surgery LLC
Anchorage Alaska, 99508, United States
Alaska Oncology and Hematology LLC
Anchorage Alaska, 99508, United States
Alaska Women's Cancer Care
Anchorage Alaska, 99508, United States
Anchorage Oncology Centre
Anchorage Alaska, 99508, United States
Katmai Oncology Group
Anchorage Alaska, 99508, United States
Providence Alaska Medical Center
Anchorage Alaska, 99508, United States
Fairbanks Memorial Hospital
Fairbanks Alaska, 99701, United States More Info
Site Public Contact
Contact
907-458-3043
[email protected]
Nicholas DiBella
Principal Investigator
Mercy Hospital Fort Smith
Fort Smith Arkansas, 72903, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank California, 91505, United States
Epic Care-Dublin
Dublin California, 94568, United States More Info
Site Public Contact
Contact
925-875-1677
Lisa Bailey
Principal Investigator
Bay Area Breast Surgeons Inc
Emeryville California, 94608, United States More Info
Site Public Contact
Contact
510-835-9900
Lisa Bailey
Principal Investigator
Epic Care Partners in Cancer Care
Emeryville California, 94608, United States More Info
Site Public Contact
Contact
510-629-6682
Lisa Bailey
Principal Investigator
Contra Costa Regional Medical Center
Martinez California, 94553, United States
Alta Bates Summit Medical Center - Summit Campus
Oakland California, 94609, United States
Bay Area Tumor Institute
Oakland California, 94609, United States
Saint Joseph Hospital - Orange
Orange California, 92868, United States More Info
Site Public Contact
Contact
714-734-6220
Timothy E. Byun
Principal Investigator
Epic Care Cyberknife Center
Walnut Creek California, 94597, United States More Info
Site Public Contact
Contact
510-465-8016
[email protected]
Lisa Bailey
Principal Investigator
Rocky Mountain Cancer Centers-Aurora
Aurora Colorado, 80012, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
The Medical Center of Aurora
Aurora Colorado, 80012, United States
Rocky Mountain Cancer Centers-Boulder
Boulder Colorado, 80304, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers - Centennial
Centennial Colorado, 80112, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Presbyterian - Saint Lukes Medical Center - Health One
Denver Colorado, 80218, United States
Rocky Mountain Cancer Centers-Midtown
Denver Colorado, 80218, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Rose
Denver Colorado, 80220, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Mountain Blue Cancer Care Center - Swedish
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers - Swedish
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Swedish Medical Center
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
The Melanoma and Skin Cancer Institute
Englewood Colorado, 80113, United States More Info
Site Public Contact
Contact
[email protected]
Nicholas DiBella
Principal Investigator
North Colorado Medical Center
Greeley Colorado, 80631, United States
Rocky Mountain Cancer Centers-Littleton
Littleton Colorado, 80120, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree Colorado, 80124, United States More Info
Site Public Contact
Contact
303-777-2663
[email protected]
Nicholas DiBella
Principal Investigator
Sky Ridge Medical Center
Lone Tree Colorado, 80124, United States
McKee Medical Center
Loveland Colorado, 80539, United States
Rocky Mountain Cancer Centers-Thornton
Thornton Colorado, 80260, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami Florida, 33136, United States More Info
Site Public Contact
Contact
305-243-2647
Mecker G. Moller
Principal Investigator
Saint Luke's Cancer Institute - Boise
Boise Idaho, 83712, United States
Saint Luke's Cancer Institute - Fruitland
Fruitland Idaho, 83619, United States
Saint Luke's Cancer Institute - Meridian
Meridian Idaho, 83642, United States
Saint Luke's Cancer Institute - Nampa
Nampa Idaho, 83686, United States
Saint Luke's Cancer Institute - Twin Falls
Twin Falls Idaho, 83301, United States
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States
Illinois CancerCare-Canton
Canton Illinois, 61520, United States
Memorial Hospital of Carbondale
Carbondale Illinois, 62902, United States
SIH Cancer Institute
Carterville Illinois, 62918, United States
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States
Centralia Oncology Clinic
Centralia Illinois, 62801, United States
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States
Western Illinois Cancer Treatment Center
Galesburg Illinois, 61401, United States
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States
Good Samaritan Regional Health Center
Mount Vernon Illinois, 62864, United States
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States
Methodist Medical Center of Illinois
Peoria Illinois, 61636, United States
Illinois CancerCare-Peru
Peru Illinois, 61354, United States
Valley Radiation Oncology
Peru Illinois, 61354, United States
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States
Illinois CancerCare - Washington
Washington Illinois, 61571, United States
Reid Health
Richmond Indiana, 47374, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Mary Greeley Medical Center
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
McFarland Clinic PC - Ames
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-239-4734
[email protected]
Debra M. Prow
Principal Investigator
McFarland Clinic PC-Boone
Boone Iowa, 50036, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge Iowa, 50501, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
McFarland Clinic PC-Jefferson
Jefferson Iowa, 50129, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
McFarland Clinic PC-Marshalltown
Marshalltown Iowa, 50158, United States More Info
Site Public Contact
Contact
515-956-4132
Debra M. Prow
Principal Investigator
Central Care Cancer Center - Garden City
Garden City Kansas, 67846, United States
Central Care Cancer Center - Great Bend
Great Bend Kansas, 67530, United States
Bronson Battle Creek
Battle Creek Michigan, 49017, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids Michigan, 49503, United States
Mercy Health Saint Mary's
Grand Rapids Michigan, 49503, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Spectrum Health at Butterworth Campus
Grand Rapids Michigan, 49503, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Bronson Methodist Hospital
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
West Michigan Cancer Center
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Ascension Borgess Cancer Center
Kalamazoo Michigan, 49009, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Borgess Medical Center
Kalamazoo Michigan, 49048, United States
Mercy Health Mercy Campus
Muskegon Michigan, 49444, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Lakeland Hospital Niles
Niles Michigan, 49120, United States
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores Michigan, 49444, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Spectrum Health Reed City Hospital
Reed City Michigan, 49677, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Lakeland Medical Center Saint Joseph
Saint Joseph Michigan, 49085, United States
Marie Yeager Cancer Center
Saint Joseph Michigan, 49085, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Munson Medical Center
Traverse City Michigan, 49684, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Metro Health Hospital
Wyoming Michigan, 49519, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin Missouri, 63011, United States
Central Care Cancer Center - Bolivar
Bolivar Missouri, 65613, United States
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States
Southeast Cancer Center
Cape Girardeau Missouri, 63703, United States
Parkland Health Center - Farmington
Farmington Missouri, 63640, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Capital Region Southwest Campus
Jefferson City Missouri, 65109, United States
Freeman Health System
Joplin Missouri, 64804, United States
Mercy Hospital Joplin
Joplin Missouri, 64804, United States
Delbert Day Cancer Institute at PCRMC
Rolla Missouri, 65401, United States
Mercy Clinic-Rolla-Cancer and Hematology
Rolla Missouri, 65401, United States
Heartland Regional Medical Center
Saint Joseph Missouri, 64506, United States
Mercy Hospital South
Saint Louis Missouri, 63128, United States
Missouri Baptist Medical Center
Saint Louis Missouri, 63131, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Mercy Hospital Saint Louis
Saint Louis Missouri, 63141, United States
Sainte Genevieve County Memorial Hospital
Sainte Genevieve Missouri, 63670, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Mercy Hospital Springfield
Springfield Missouri, 65804, United States
CoxHealth South Hospital
Springfield Missouri, 65807, United States
Missouri Baptist Sullivan Hospital
Sullivan Missouri, 63080, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills Missouri, 63127, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Saint Patrick Hospital - Community Hospital
Missoula Montana, 59802, United States More Info
Site Public Contact
Contact
406-327-3118
[email protected]
Alison K. Conlin
Principal Investigator
Indu and Raj Soin Medical Center
Beavercreek Ohio, 45431, United States
Dayton Physicians LLC-Miami Valley South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Miami Valley Hospital South
Centerville Ohio, 45459, United States
Oncology Hematology Care Inc-Kenwood
Cincinnati Ohio, 45236, United States
Miami Valley Hospital
Dayton Ohio, 45409, United States
Dayton Physician LLC-Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Miami Valley Hospital North
Dayton Ohio, 45415, United States
Armes Family Cancer Center
Findlay Ohio, 45840, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Blanchard Valley Hospital
Findlay Ohio, 45840, United States
Orion Cancer Care
Findlay Ohio, 45840, United States
Atrium Medical Center-Middletown Regional Hospital
Franklin Ohio, 45005, United States
Dayton Physicians LLC-Atrium
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Dayton Physicians LLC-Wayne
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Wayne Hospital
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Greater Dayton Cancer Center
Kettering Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Kettering Medical Center
Kettering Ohio, 45429, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Springfield Regional Cancer Center
Springfield Ohio, 45504, United States
Springfield Regional Medical Center
Springfield Ohio, 45505, United States
Dayton Physicians LLC-Upper Valley
Troy Ohio, 45373, United States
Upper Valley Medical Center
Troy Ohio, 45373, United States
Mercy Hospital Oklahoma City
Oklahoma City Oklahoma, 73120, United States
Saint Charles Health System
Bend Oregon, 97701, United States
Clackamas Radiation Oncology Center
Clackamas Oregon, 97015, United States
Providence Cancer Institute Clackamas Clinic
Clackamas Oregon, 97015, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Alison K. Conlin
Principal Investigator
Bay Area Hospital
Coos Bay Oregon, 97420, United States
Providence Newberg Medical Center
Newberg Oregon, 97132, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Alison K. Conlin
Principal Investigator
Providence Portland Medical Center
Portland Oregon, 97213, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Alison K. Conlin
Principal Investigator
Providence Saint Vincent Medical Center
Portland Oregon, 97225, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Alison K. Conlin
Principal Investigator
Saint Luke's Cancer Center - Allentown
Allentown Pennsylvania, 18104, United States More Info
Site Public Contact
Contact
610-776-4714
Melissa A. Wilson
Principal Investigator
Saint Luke's University Hospital-Bethlehem Campus
Bethlehem Pennsylvania, 18015, United States More Info
Site Public Contact
Contact
484-503-4151
Melissa A. Wilson
Principal Investigator
Saint Luke's Hospital-Anderson Campus
Easton Pennsylvania, 18045, United States More Info
Site Public Contact
Contact
[email protected]
Melissa A. Wilson
Principal Investigator
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh Pennsylvania, 15232, United States More Info
Site Public Contact
Contact
412-647-8073
Diwakar Davar
Principal Investigator
Saint Luke's Hospital-Quakertown Campus
Quakertown Pennsylvania, 18951, United States More Info
Site Public Contact
Contact
[email protected]
Melissa A. Wilson
Principal Investigator
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Vermont, 05602, United States More Info
Site Public Contact
Contact
802-225-5400
Hibba Tul Rehman
Principal Investigator
University of Vermont Medical Center
Burlington Vermont, 05401, United States More Info
Site Public Contact
Contact
802-656-4101
[email protected]
Hibba Tul Rehman
Principal Investigator
University of Virginia Cancer Center
Charlottesville Virginia, 22908, United States More Info
Site Public Contact
Contact
434-243-6303
[email protected]
Elizabeth M. Gaughan
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
Andrew Poklepovic
Principal Investigator
Providence Regional Cancer System-Aberdeen
Aberdeen Washington, 98520, United States
PeaceHealth Saint Joseph Medical Center
Bellingham Washington, 98225, United States
Providence Regional Cancer System-Centralia
Centralia Washington, 98531, United States
Swedish Cancer Institute-Edmonds
Edmonds Washington, 98026, United States
Providence Regional Cancer Partnership
Everett Washington, 98201, United States
Swedish Cancer Institute-Issaquah
Issaquah Washington, 98029, United States
Kadlec Clinic Hematology and Oncology
Kennewick Washington, 99336, United States More Info
Site Public Contact
Contact
509-783-4637
[email protected]
Alison K. Conlin
Principal Investigator
Providence Regional Cancer System-Lacey
Lacey Washington, 98503, United States
PeaceHealth Saint John Medical Center
Longview Washington, 98632, United States
Jefferson Healthcare
Port Townsend Washington, 98368, United States More Info
Site Public Contact
Contact
360-344-3091
Nicholas DiBella
Principal Investigator
Swedish Medical Center-Ballard Campus
Seattle Washington, 98107, United States
Swedish Medical Center-First Hill
Seattle Washington, 98122, United States
PeaceHealth United General Medical Center
Sedro-Woolley Washington, 98284, United States
PeaceHealth Southwest Medical Center
Vancouver Washington, 98664, United States More Info
Site Public Contact
Contact
360-514-3940
[email protected]
Alison K. Conlin
Principal Investigator
Providence Saint Mary Regional Cancer Center
Walla Walla Washington, 99362, United States
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Demet Gokalp Yasar
Principal Investigator
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Site Public Contact
Contact
414-805-3666
Amy K. Harker-Murray
Principal Investigator
Marshfield Clinic-Minocqua Center
Minocqua Wisconsin, 54548, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Demet Gokalp Yasar
Principal Investigator
Marshfield Medical Center-Rice Lake
Rice Lake Wisconsin, 54868, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Demet Gokalp Yasar
Principal Investigator
Marshfield Medical Center-River Region at Stevens Point
Stevens Point Wisconsin, 54482, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Demet Gokalp Yasar
Principal Investigator
Marshfield Medical Center - Weston
Weston Wisconsin, 54476, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Demet Gokalp Yasar
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

54

Study ID:

NCT04708418

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.